文献速递炎症性肠病

多供体粪菌移植联合抗炎饮食诱导后单用抗炎饮食维持轻中度溃疡性结肠炎缓解1年有效:一项随机对照试验

Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial.
PubMed 文献 · Gut · 2022-08-16

本开放标签随机对照试验将轻中度活动性溃疡性结肠炎患者按1:1随机分为粪菌移植联合抗炎饮食组(FMT-AID)与优化标准药物治疗组(SMT)。FMT-AID组接受7次每周结肠镜灌注多供体新鲜粪菌并配合抗炎饮食,SMT组优化基线药物。8周时FMT-AID组临床应答、缓解及深度缓解率均优于SMT组;48周时抗炎饮食维持深度缓解优于SMT。

要点

  • 8周时FMT-AID组临床应答65.7%优于SMT组35.5%,OR 3.5。
  • 8周时FMT-AID组深度缓解36.4%优于SMT组8.7%,OR 6.0。
  • 48周时抗炎饮食维持深度缓解25%优于SMT组0%,p=0.007。

核心结论

  • 多供体粪菌移植联合抗炎饮食可有效诱导轻中度溃疡性结肠炎深度缓解,并单用抗炎饮食维持缓解至1年。

研究设计与样本

  • 开放标签随机对照试验,将轻中度(SCCAI 3-9)内镜下活动性(UCEIS>1)且基线用药稳定的溃疡性结肠炎患者按1:1随机分组。
  • 筛查113例,随机73例,改良意向性治疗分析纳入66例(FMT-AID组35例,SMT组31例)。
  • FMT-AID组接受7次每周结肠镜灌注来自多个农村供体的新鲜粪菌(第0-6周)并配合抗炎饮食;SMT组优化基线药物。
  • 两组的临床应答者(SCCAI下降>3)随访至48周,维持基线用药(FMT-AID组继续抗炎饮食)。

主要发现

  • 8周时FMT-AID组临床应答23/35(65.7%)优于SMT组11/31(35.5%),p=0.01,OR 3.5(95%CI 1.3至9.6)。
  • 8周时FMT-AID组缓解21/35(60%)优于SMT组10/31(32.3%),p=0.02,OR 3.2(95%CI 1.1至8.7)。
  • 8周时FMT-AID组深度缓解12/33(36.4%)优于SMT组2/23(8.7%),p=0.03,OR 6.0(95%CI 1.2至30.2)。
  • 48周时抗炎饮食组维持深度缓解6/24(25%)优于SMT组0/27,p=0.007。

关键数值与推荐

  • 主要结局指标为8周时的临床应答和深度缓解(临床SCCAI<2;内镜UCEIS<1),以及48周时的深度缓解和无激素临床缓解。
  • 临床应答定义为SCCAI下降>3。
  • 纳入标准为轻中度(SCCAI 3-9)内镜下活动性(UCEIS>1)溃疡性结肠炎且基线用药稳定。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Microbiome and dietary manipulation therapies are being explored for treating ulcerative colitis (UC). We aimed to examine the efficacy of multidonor faecal microbiota transplantation (FMT) and anti-inflammatory diet in inducing remission followed by long-term maintenance with anti-inflammatory diet in patients with mild-moderate UC. DESIGN: This open-labelled randomised controlled trial (RCT) randomised patients with mild-moderate (Simple Clinical Colitis Activity Index (SCCAI) 3-9) endoscopically active UC (Ulcerative Colitis Endoscopic Index of Severity (UCEIS)>1) on stable baseline medications in 1:1 ratio to FMT and anti-inflammatory diet (FMT-AID) versus optimised standard medical therapy (SMT). The FMT-AID arm received seven weekly colonoscopic infusions of freshly prepared FMT from multiple rural donors(weeks 0-6) with anti-inflammatory diet. Baseline medications were optimised in the SMT arm. Clinical responders (decline in SCCAI>3) at 8 weeks in both arms were followed until 48 weeks on baseline medications (with anti-inflammatory diet in the FMT-AID arm). Primary outcome measures were clinical response and deep remission (clinical-SCCAI <2; and endoscopic-UCEIS <1) at 8 weeks, and deep remission and steroid-free clinical remission at 48 weeks. RESULTS: Of the 113 patients screened, 73 were randomised, and 66 were included in (35-FMT-AID; 31-SMT) modified intention-to-treat analysis (age-35.7±11.1 years; male-60.1%; disease duration-48 (IQR 24-84) months; pancolitis-34.8%; SCCAI-6 (IQR 5-7); UCEIS-4 (IQR 3-5)). Baseline characteristics were comparable. FMT-AID was superior to SMT in inducing clinical response (23/35 (65.7%) vs 11/31 (35.5%), p=0.01, OR 3.5 (95% CI 1.3 to 9.6)), remission (21/35 (60%) vs 10/31 (32.3%), p=0.02, OR 3.2 (95% CI 1.1 to 8.7)) and deep remission (12/33 (36.4%) vs 2/23 (8.7%), p=0.03, OR 6.0 (95% CI 1.2 to 30.2)) at 8 weeks. Anti-inflammatory diet was superior to SMT in maintaining deep remission until 48 weeks (6/24 (25%) vs 0/27, p=0.007). CONCLUSION: Multidonor FMT with anti-inflammatory diet effectively induced deep remission in mild-moderate UC which was sustained with anti-inflammatory diet over 1 year. TRIAL REGISTRATION NUMBER: ISRCTN15475780.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kedia S, Virmani S, K Vuyyuru S, et al. Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial. Gut. 2022. PMID: 35973787. doi:10.1136/gutjnl-2022-327811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。